Gilead Sciences, Inc.Gilead Sciences, Inc.Gilead Sciences, Inc.

Gilead Sciences, Inc.

No trades
See on Supercharts
Next report date
Report period
EPS estimate
Revenue estimate
Market capitalization
‪114.82 B‬USD
0.10USD
‪5.66 B‬USD
‪27.06 B‬USD
‪1.24 B‬
Beta (1Y)
0.54
Employees (FY)
‪18 K‬
Change (1Y)
‪+1 K‬ +5.88%
Revenue / Employee (1Y)
‪1.50 M‬USD
Net income / Employee (1Y)
‪314.67 K‬USD

About Gilead Sciences, Inc.


CEO
Daniel P. O'Day
Website
Headquarters
Foster City
Founded
1987
FIGI
BBG000CKGBP2
Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬

See all ideas 

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
GILD5050849
Gilead Sciences, Inc. 2.8% 01-OCT-2050
Yield to maturity
6.21%
Maturity date
Oct 1, 2050
US375558BS1
GILEAD SCIEN 20/40
Yield to maturity
5.98%
Maturity date
Oct 1, 2040
US375558BK8
GILEAD SCIENCES 16/47
Yield to maturity
5.70%
Maturity date
Mar 1, 2047
GILD4184058
Gilead Sciences, Inc. 4.5% 01-FEB-2045
Yield to maturity
5.51%
Maturity date
Feb 1, 2045
GISE
GILEAD SCIENCES 2046
Yield to maturity
5.50%
Maturity date
Mar 1, 2046
GILD4184056
Gilead Sciences, Inc. 3.5% 01-FEB-2025
Yield to maturity
5.42%
Maturity date
Feb 1, 2025
GILD4104362
Gilead Sciences, Inc. 4.8% 01-APR-2044
Yield to maturity
5.41%
Maturity date
Apr 1, 2044
GILD5939386
Gilead Sciences, Inc. 5.6% 15-NOV-2064
Yield to maturity
5.31%
Maturity date
Nov 15, 2064
GISG
GILEAD SCIENCES 16/36
Yield to maturity
5.22%
Maturity date
Sep 1, 2036
GILD5939385
Gilead Sciences, Inc. 5.5% 15-NOV-2054
Yield to maturity
5.17%
Maturity date
Nov 15, 2054
GILD.GO
Gilead Sciences, Inc. 5.65% 01-DEC-2041
Yield to maturity
5.17%
Maturity date
Dec 1, 2041

Explore more bonds 

Frequently Asked Questions


The current price of GILD is 92.13 USD — it has decreased by −1.35% in the past 24 hours. Watch Gilead Sciences, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Gilead Sciences, Inc. stocks are traded under the ticker GILD.
GILD stock has fallen by −0.76% compared to the previous week, the month change is a 1.24% rise, over the last year Gilead Sciences, Inc. has showed a 15.77% increase.
We've gathered analysts' opinions on Gilead Sciences, Inc. future price: according to them, GILD price has a max estimate of 125.00 USD and a min estimate of 73.00 USD. Watch GILD chart and read a more detailed Gilead Sciences, Inc. stock forecast: see what analysts think of Gilead Sciences, Inc. and suggest that you do with its stocks.
GILD reached its all-time high on Jun 24, 2015 with the price of 123.37 USD, and its all-time low was 0.21 USD and was reached on Jun 8, 1994. View more price dynamics on GILD chart.
See other stocks reaching their highest and lowest prices.
GILD stock is 2.38% volatile and has beta coefficient of 0.54. Track Gilead Sciences, Inc. stock price on the chart and check out the list of the most volatile stocks — is Gilead Sciences, Inc. there?
Today Gilead Sciences, Inc. has the market capitalization of ‪114.82 B‬, it has decreased by −1.07% over the last week.
Yes, you can track Gilead Sciences, Inc. financials in yearly and quarterly reports right on TradingView.
Gilead Sciences, Inc. is going to release the next earnings report on Feb 11, 2025. Keep track of upcoming events with our Earnings Calendar.
GILD earnings for the last quarter are 2.02 USD per share, whereas the estimation was 1.53 USD resulting in a 32.02% surprise. The estimated earnings for the next quarter are 1.72 USD per share. See more details about Gilead Sciences, Inc. earnings.
Gilead Sciences, Inc. revenue for the last quarter amounts to ‪7.54 B‬ USD, despite the estimated figure of ‪7.02 B‬ USD. In the next quarter, revenue is expected to reach ‪7.15 B‬ USD.
GILD net income for the last quarter is ‪1.25 B‬ USD, while the quarter before that showed ‪1.61 B‬ USD of net income which accounts for −22.37% change. Track more Gilead Sciences, Inc. financial stats to get the full picture.
Yes, GILD dividends are paid quarterly. The last dividend per share was 0.77 USD. As of today, Dividend Yield (TTM)% is 3.32%. Tracking Gilead Sciences, Inc. dividends might help you take more informed decisions.
Gilead Sciences, Inc. dividend yield was 3.70% in 2023, and payout ratio reached 66.62%. The year before the numbers were 3.40% and 80.25% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
As of Dec 8, 2024, the company has ‪18.00 K‬ employees. See our rating of the largest employees — is Gilead Sciences, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Gilead Sciences, Inc. EBITDA is ‪13.35 B‬ USD, and current EBITDA margin is 45.96%. See more stats in Gilead Sciences, Inc. financial statements.
Like other stocks, GILD shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Gilead Sciences, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Gilead Sciences, Inc. technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Gilead Sciences, Inc. stock shows the buy signal. See more of Gilead Sciences, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.